Adamas Pharmaceuticals, Inc. (ADMS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADMS Stock Price Chart Interactive Chart >
ADMS Price/Volume Stats
|Current price||$8.22||52-week high||$9.15|
|Prev. close||$8.16||52-week low||$4.02|
|Day high||$8.25||Avg. volume||692,487|
|50-day MA||$6.93||Dividend yield||N/A|
|200-day MA||$5.54||Market Cap||376.37M|
Adamas Pharmaceuticals, Inc. (ADMS) Company Bio
Adamas Pharmaceuticals is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company was founded in 2000 and is based in Emeryville, California.
Most Popular Stories View All
ADMS Latest News Stream
|Loading, please wait...|
ADMS Latest Social Stream
View Full ADMS Social Stream
Latest ADMS News From Around the Web
Below are the latest news stories about Adamas Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADMS as an investment opportunity.
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flowROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). “Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue,” said Jack Khattar, President and CEO of Supern
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus’ proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Com
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, NY / ACCESSWIRE / November 12, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) relating to its proposed acquisition by Supernus Pharmaceuticals, Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP is Investigating the Following Companies - BCML, GWB, ABTX, ESBK, ADMS, ACBI
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, ADMS, and ACBI Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
ADMS Price Returns
Continue Researching ADMSHere are a few links from around the web to help you further your research on Adamas Pharmaceuticals Inc's stock as an investment opportunity:
Adamas Pharmaceuticals Inc (ADMS) Stock Price | Nasdaq
Adamas Pharmaceuticals Inc (ADMS) Stock Quote, History and News - Yahoo Finance
Adamas Pharmaceuticals Inc (ADMS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...